NUMELVI DIN 02566559
Status: Marketed
Holder: INTERVET CANADA CORP
Health Canada record
| Active ingredient(s) | ATINVICITINIB 4.8 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 09-May-2026 |
|---|
| Current status date | 09-May-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Intervet Canada Corp. — licence 100147, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ATINVICITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02566567 | NUMELVI | INTERVET CANADA CORP | Tablet | ATINVICITINIB 7.2 MG | Marketed |
| 02566575 | NUMELVI | INTERVET CANADA CORP | Tablet | ATINVICITINIB 21.6 MG | Marketed |
| 02566583 | NUMELVI | INTERVET CANADA CORP | Tablet | ATINVICITINIB 31.6 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37063 | 2026-03-09 | New Drug Submission (NDS) | |
Request a quote for NUMELVI
How to read a Canadian DIN record